FRT vs IKT · rev $1.28B vs $215.2M cap
FRT (FRT) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
FRT currently screens at market cap $0. IKT currently screens at market cap $215.2M.
Not investment advice. Open the FRT and IKT stock pages for the full models.
Not investment advice.